Bayer HealthCare Pharmaceuticals’ investigational radium-223 chloride has met the primary and secondary endpoints of a Phase III prostate cancer trial.

The randomised double-blind and placebo-controlled trial showed that radium-223 chloride improved overall survival in 44% of patients with castration-resistant prostate cancer and symptomatic bone metastases.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Radium-223 chloride demonstrated median overall survival of 14 months, compared to 11.2 months for the placebo group, a 49% improvement in time to prostate-specific antigen progression, and 33% of patients showed total alkaline phosphatise normalisation compared to 1% for placebo group.

The primary endpoint of the study was overall survival, while secondary endpoints included time to occurrence of SREs, changes and time to progression in prostate-specific antigen and alkaline phosphatise, safety and impact on quality of life measures.

Trial investigator Oliver Sartor said radium-223 chloride is the first bone-targeted, alpha-emitting radiopharmaceutical to demonstrate a survival benefit in men with castration-resistant prostate cancer and symptomatic bone metastases.

The company plans to file a new drug application with the US Food and Drug Administration in mid-2012.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now